RxDoctor Payments Data

Allen Pettee, MD

Neurology · Rochester, NYNPI 1780671511

Payments from drug & device makers

$6,326in general payments, 2019–2025

Across 416 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Genentech USA, Inc.$694
  • Supernus Pharmaceuticals, Inc.$604
  • Novartis$552
  • Teva Pharmaceuticals USA, Inc.$547
  • EMD Serono, Inc.$498
  • plus $2K from 38 others

What the payments were for

  • Speaking & faculty fees$130%
  • Food & beverage$6,17998%
  • Education$1342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,326 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$811,965
Medicare patients
226
Services billed
32,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide57$526,205
MayzentSiponimod46$474,984
CopaxoneGlatiramer Acetate48$319,569
Avonex Pen (4 Pack)Interferon Beta-1a25$218,054
Nurtec OdtRimegepant Sulfate142$190,337
Dalfampridine ErDalfampridine213$189,278
Aimovig AutoinjectorErenumab-Aooe208$176,969
Avonex (4 Pack)Interferon Beta-1a22$165,743
Dimethyl Fumarate35$157,399
UbrelvyUbrogepant131$131,538
LamictalLamotrigine35$131,493
RebifInterferon Beta-1a/Albumin12$130,624
Teriflunomide68$124,108
AmpyraDalfampridine24$113,132
TecfideraDimethyl Fumarate12$111,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$100$526,20557 claims
NovartisMayzent$552$474,98446 claims
BiogenAvonex (4 Pack), Tecfidera, Tysabri$180$366,56645 claims
Teva Pharmaceuticals USA, Inc.Copaxone$547$319,56948 claims
PfizerNurtec Odt, Dilantin$142$198,776173 claims
AbbVieUbrelvy, Qulipta$1,058$181,890180 claims
EMD Serono, Inc.Rebif$498$130,62412 claims
Acorda Therapeutics, IncAmpyra$13$113,13224 claims
Sunovion Pharmaceuticals Inc.Aptiom$220$101,50123 claims
Neurocrine Biosciences, Inc.Ingrezza$78$101,16613 claims
UCB, Inc.Vimpat, Neupro$33$58,29756 claims
Lilly USA, LLCReyvow$123$13,31619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →